Assessment of Anti-β2 glycoprotein1 antibody in Systemic Lupus Erythrematosus Patients.

Secondary anti-phospolipid syndrome (APS) is diagnosed in many patients with systemic lupus erythrematosus (SLE) especially with thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for anti-phospholipid antibody (aPL). In this work, we aimed to detect the prevalence of IgG and IgA anti-β2 glycoprotein1 (β2GP1) in SLE patients. Serum samples were collected from 50 female patients with SLE (25 had APS and 25 patients who did not have APS), in addition to 22 apparently healthy females with matched age as a control group.